Menta Capital’s TherapeuticsMD TXMD Stock Holding History

Menta Capital’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$86K	Buy	660 +428	+184%	+$76.7K	0.04%	450
2019 Q1	$56K	Buy	+232	New	+$61.4K	0.02%	461
2018 Q4	–	Sell	-234	Closed	-$77K	–	671
2018 Q3	$77K	Buy	+234	New	+$71.7K	0.03%	535
2018 Q1	–	Sell	-2,223	Closed	-$671K	–	752
2017 Q4	$671K	Buy	+2,223	New	+$619K	0.13%	288
2017 Q1	–	Sell	-1,376	Closed	-$397K	–	987
2016 Q4	$397K	Sell	1,376 -1,358	-50%	-$421K	0.03%	679
2016 Q3	$931K	Buy	2,734 +1,671	+157%	+$610K	0.09%	387
2016 Q2	$452K	Sell	1,063 -705	-40%	-$291K	0.06%	544
2016 Q1	$566K	Buy	1,768 +863	+95%	+$294K	0.08%	442
2015 Q4	$469K	Sell	905 -179	-17%	-$66.1K	0.06%	505
2015 Q3	$318K	Buy	1,084 +818	+308%	+$291K	0.05%	544
2015 Q2	$104K	Sell	266 -103	-28%	-$36.3K	0.02%	634
2015 Q1	$112K	Sell	369 -1,778	-83%	-$434K	0.01%	663
2014 Q4	$478K	Buy	2,147 +1,337	+165%	+$276K	0.07%	439
2014 Q3	$188K	Buy	+810	New	+$204K	0.03%	539
2014 Q2	–	Sell	-346	Closed	-$109K	–	586
2014 Q1	$109K	Buy	346 +60	+21%	+$19.1K	0.03%	356
2013 Q4	$74K	Buy	+286	New	+$62.6K	0.03%	351

Other funds holding TXMD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Menta Capital's TXMD Position: Q2 2019 in Review

Menta Capital increased its TherapeuticsMD (TXMD) stake by 184% in Q2 2019, buying an estimated $76.7K and bringing the position to 660 shares worth $86K. The position accounts for 0.04% of the portfolio, ranked #450.

Menta Capital first reported a position in TXMD in Q4 2013 and has held it in 16 quarters since. The position peaked at $931K in Q3 2016. 148 funds tracked by Wall St. Rank hold TXMD as of Q2 2019.

Menta Capital held 660 shares of TherapeuticsMD worth $86K as of Q2 2019.
Menta Capital bought 428 TherapeuticsMD shares in Q2 2019, an estimated $76.7K.
TherapeuticsMD made up 0.04% of Menta Capital's portfolio in Q2 2019, its #450 holding.
Menta Capital first reported a position in TherapeuticsMD in Q4 2013 and has held it in 16 quarters since.
Menta Capital's TherapeuticsMD position peaked at $931K in Q3 2016.
148 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2019.

Based on Menta Capital's 13F filing for Q2 2019, filed 7 Aug 2019.